Kodiak Sciences Inc.
KOD
Kedudukan dalam Saham
#3153
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Harga Saham
$90.83
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.71B
Perubahan (1 hari)
5.92%
Perubahan (1 tahun)
413.16%
Negara
US
Perdagangan Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
Bilangan saham terbitan bagi Kodiak Sciences Inc. (KOD)
Bilangan saham terbitan setakat June 2026: 62.63M
Menurut laporan kewangan terkini dan harga saham Kodiak Sciences Inc., bilangan saham terbitan semasa ialah 62.63M. Pada akhir December 2023, syarikat mempunyai 52.41M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Kodiak Sciences Inc. (KOD) dari 2016 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 62.63M | 19.10% |
| 2024 | 52.58M | 0.32% |
| 2023 | 52.41M | 0.31% |
| 2022 | 52.25M | 0.89% |
| 2021 | 51.79M | 13.22% |
| 2020 | 45.74M | 20.84% |
| 2019 | 37.85M | 5.53% |
| 2018 | 35.87M | 35.08% |
| 2017 | 26.56M | 256.75% |
| 2016 | 7.44M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 305.41% |
US
|
|
| 396.00M | 532.30% |
US
|
|
| 478.91M | 664.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -0.71% |
NL
|
